Immunogenicity of a Psoralen-Inactivated Dengue Virus Type 1 Vaccine Candidate in Mice - Test2 - elhamkhani - TriplyDB

Immunogenicity of a Psoralen-Inactivated Dengue Virus Type 1 Vaccine Candidate in Mice

Immunogenicity of a Psoralen-Inactivated Dengue Virus Type 1 Vaccine Candidate in Mice

http://www.wikidata.org/entity/Q27490882

about

Can biowarfare agents be defeated with light?Development and evaluation of single domain antibodies for vaccinia and the L1 antigen Immunogenic Properties of a BCG Adjuvanted Chitosan Nanoparticle-Based Dengue Vaccine in Human Dendritic Cells.Psoralen Inactivation of Viruses: A Process for the Safe Manipulation of Viral Antigen and Nucleic Acid.Dengue virus photo-inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen compound (4'-aminomethyl-trioxsalen) is highly immunogenic in mice.Photochemical inactivation of alpha- and poxviruses.

P2860

Q28396096-B799A95F-985B-47B9-B903-F47B2C6FB3BC Q35248202-CF98C5C2-F241-4B17-981C-C0D6EE1A594B Q35783544-F2EE3C28-490F-47AB-9384-13856EDAC888 Q36333651-3BAC36FD-F277-4A9E-87EB-153F9F40A211 Q37694855-F60FF030-9A33-4E57-B89D-7EA5847936D8 Q54350515-C83B4136-F75B-4D5F-9F07-64F83E0D0171

P2860

Immunogenicity of a Psoralen-Inactivated Dengue Virus Type 1 Vaccine Candidate in Mice

http://www.wikidata.org/entity/Q27490882

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Immunogenicity of a Psoralen-Inactivated Dengue Virus Type 1 Vaccine Candidate in Mice

@ast

Immunogenicity of a Psoralen-Inactivated Dengue Virus Type 1 Vaccine Candidate in Mice

@en

Immunogenicity of a Psoralen-Inactivated Dengue Virus Type 1 Vaccine Candidate in Mice

@nl

type

label

Immunogenicity of a Psoralen-Inactivated Dengue Virus Type 1 Vaccine Candidate in Mice

@ast

Immunogenicity of a Psoralen-Inactivated Dengue Virus Type 1 Vaccine Candidate in Mice

@en

Immunogenicity of a Psoralen-Inactivated Dengue Virus Type 1 Vaccine Candidate in Mice

@nl

prefLabel

Immunogenicity of a Psoralen-Inactivated Dengue Virus Type 1 Vaccine Candidate in Mice

@ast

Immunogenicity of a Psoralen-Inactivated Dengue Virus Type 1 Vaccine Candidate in Mice

@en

Immunogenicity of a Psoralen-Inactivated Dengue Virus Type 1 Vaccine Candidate in Mice

@nl

P1433

Q27490882-5960CE7F-D537-4198-AC2B-411BD26A686A

P1476

Q27490882-EB060E5E-726B-40DE-8109-6036BB33FB50

P2093

Q27490882-D91232D6-663B-4B4D-A748-DB9D511F7C52

Q27490882-F43C19DD-2AED-4D10-AFD7-11B1D8D3CC5C

P2860

Q27490882-0C19F408-656C-422C-B24A-83F584AE27AC

Q27490882-3C240F18-29BF-4EC7-8D03-C68C25F88698

Q27490882-404FBEF2-D8FD-497A-80FF-1EEB15DA6AF4

Q27490882-4C775240-6FB0-456E-83FC-47B8F08C0C8B

Q27490882-538B6CDB-9A1E-40E4-9621-4998D93F90A3

Q27490882-5577D5FB-F8B4-4847-9D32-E07C72AB4339

Q27490882-933D8E9D-F087-478B-9CCE-4084DF2E17C0

Q27490882-ADFB6305-208F-43B5-9D91-DAE4998E1F95

Q27490882-B635FA90-9B2B-44D4-9205-DC3B61AA4294

Q27490882-EC771E5C-5C57-4BE8-871B-E2A637F35A67

P304

Q27490882-2CCF3280-08C7-4F64-98C7-1C0863B86E06

P31

Q27490882-6E1F5C8E-9474-4555-ACA1-5E11473609C4

P356

Q27490882-CAF263C0-0122-4E4E-934F-A9EA8043417A

P433

Q27490882-130E2E9E-B367-4C3F-8B46-9AC8594B167B

P478

Q27490882-87758CD0-A3C8-4DFB-9AFC-5E84383F478D

P50

Q27490882-55E272E8-54D3-4FDD-9664-30B7906A4CFE

Q27490882-A21CE311-715D-474F-995C-F6F5E89FBBF2

P577

Q27490882-62E69AB6-10C5-4BB6-88F8-0055CD2EC118

P698

Q27490882-F27DB3F7-6973-41DD-89BB-1ADE82A60A61

P921

Q27490882-067C6694-9582-4863-8E51-5846080C37B1

Q27490882-51F9CFEF-AD0E-41A5-BDD8-710A98D4F413

P932

Q27490882-2BB50011-5409-4584-8493-7941231722B5

P356

P1433

Clinical and Vaccine Immunology

P1476

Immunogenicity of a psoralen-inactivated dengue virus type 1 vaccine candidate in mice

@en

P2093

Kevin R Porter

http://www.w3.org/2001/XMLSchema#string

Tadeusz J Kochel

http://www.w3.org/2001/XMLSchema#string

P2860

Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization

Review of accidents caused by incomplete inactivation of viruses.

The role of photochemical treatment with amotosalen and UV-A light in the prevention of transfusion-transmitted cytomegalovirus infections.

Photochemical inactivation of DNA and RNA viruses by psoralen derivatives.

Psoralen photochemistry and nucleic acid structure.

An overview of the inactivation of FMDV and the implications when residual virus is present in vaccines.

Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function.

Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light.

Quantification of viral inactivation by photochemical treatment with amotosalen and UV A light, using a novel polymerase chain reaction inhibition method with preamplification.

A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines

P304

304-306

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/CVI.00353-09

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Roger M Castillo Oré

P577

2009-12-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20007362

http://www.w3.org/2001/XMLSchema#string

P921

clinical chemistry

P932

2815535

http://www.w3.org/2001/XMLSchema#string